worldometer covid vaccine

Coronavirus News Highlights: Oxford-AstraZeneca COVID-19 vaccine 'very issued an emergency use authorization for Johnson & Johnsons vaccine, making it the third coronavirus vaccine available in the United States. With massive support from the U.S. government, Maryland-based Novavax developed a highly effective protein-based vaccine in 2020. Two days later, the United States followed suit. Storage: Stable at room temperature for three months Lowest new cases/100k - 7 day On April 25, 2022, SK Bioscience announced the results of its Phase 3 trial. The Phase 1/2 trial, conducted in the spring of 2020, showed that the vaccine produced antibodies in volunteers, some of whom experienced fevers and other side effects. In addition to its project with Themis, Merck partnered with IAVI on a second viral vector vaccine. On July 29, Moderna announced a deal with the United States government to provide 66 million booster shots, containing RNA for the original spike protein, as well as one shared by BA.4 and BA.5.Modernas Omicron booster won conditional approval from the United Kingdom on Aug. 15, 2022. The vaccine contains small portions of viral proteins, known as peptides. Type: Muscle injection In December 2020, the Korea Biomedical Review reported that Genexine got disappointing results from their initial formulation and decided to restart their trials with a modified vaccine.On Jan. 20, 2021, the company registered a Phase 1/2 trial, and in June they registered a Phase 1 trial specifically for elderly volunteers. Chinese researchers at Shanghai Zerun Biotechnology and Walvax Biotechnology have modified the structure of the coronavirus spike protein to better stimulate an immune response from their vaccine. Data contains VAERS reports processed as of February 26. VARIANTSBharat ran its clinical trials in India just as the Delta variant was rising to dominance in the country. Comrinaty received full approval for adolescents 12 and older on July 8, 2022.As of July 3, 2022, Pfizer had delivered more than 3.6 billion doses of Comirnaty to 180 countries and territories. OurWorldInData.org/coronavirus CC BY chart map table sources Download All our related research and data Charts gave emergency approval for Sinopharms vaccine to use on health care workers, and soon government officials and others were also receiving it. After successful experiments in animals, a Phase 1 trial was launched in the United Kingdom in January 2021.In March 2022, Codagenix announced that people who received CoviLiv produced a strong response from antibodies in the nose, which appears to block the spread of the virus. US states APPROVED IN U.S., ELSEWHERE Sinopharm then launched a global Phase 3 trial of the Wuhan vaccine. In people who had not previously had Covid, the Medigen produced significantly higher antibody levels than AstraZenecas vaccines. VACCINE DEVELOPMENTThe work that led to the vaccine started a decade ago at Beth Israel Deaconess Medical Center in Boston, where researchers developed a method for making vaccines out of a virus called Adenovirus 26, or Ad26 for short. Results from a pediatric study suggest that the vaccines efficacy was 82 percent against the Delta variant.On Feb. 28, 2022, Novavax released results from a six-month follow up on its Phase 3 clinical trial in the United Kingdom. AUTHORIZATIONOn Jan. 3, 2021, the Indian government granted Covaxin emergency authorization. He also said that VIDO is working with the Institut Pasteur in Senegal to market the vaccine in Africa. Vaxine took the unprecedented move of starting a crowdfunding campaign in October 2021 to raise funds for their efforts. Positive results pushed Moderna to announce that it would apply for emergency use authorization in children younger than six on March 23, 2022. It lifts the efficacy of the vaccine to 92.4 percent, and 100 percent against severe Covid-19. Endorsed by the Africa Regulatory Taskforce. Updated June 13, 2022, PHASE 3 Researchers later pointed to the vaccine dosage along with the rise of new variants as potential reasons for the low efficacy. expanded its authorization for adolescents 12 through 15 on Jan. 3, 2022. That assumption turned out to be wrong. By the time the F.D.A. It contains a coronavirus protein called nucleocapsid. Their vaccine can teach the body to develop an immune response against 11 different proteins of the coronavirus. Phase 3 trials are also large enough to reveal evidence of relatively rare side effects. Eyegene received approval to conduct a Phase 1/2 booster trial of EG-COVID in Australia on Feb. 21, 2022. Corbevax is a protein-based vaccine initially authorized in India in December 2021, and then as a booster in June 2022. Vaccines and immunization: What is vaccination? The AstraZeneca vaccine only produced antibodies in 79 percent.With SKYCovione going into use, SK Bioscience launched a Phase 3 trial of the vaccine as a booster on August 15, 2022. PHASE 3 NDV is a bird pathogen and does not cause symptoms in humans. Once the pill reaches the gut, the spores start to grow and produce parts of coronavirus proteins. Dose: 2 doses, 4 weeks apart Updated Oct. 19, 2021, PHASE 3 The vaccine, called VBI-2902a, uses aluminum phosphate as an adjuvant. This relatively low result may have been the result of the trial taking place after variants of concerns were widespread. COVID-19 vaccines - World Health Organization As a result, the U.S. government decided in April 2021 to stop supporting Inovios trial.On Aug. 26, 2021, Inovio announced that Brazilian regulators authorized their Phase 3 trial, and in September they announced that they had received approval for another Phase 3 trial in the Philippines and in Mexico. The South Korean vaccine company SK Bioscience licensed the vaccine and partnered with GSK, to launch a Phase 1/2 trial of the vaccine in February 2021. CoronaVac is also part of a mixed-vaccine trial with Inovios vaccine. In the study, the researchers will also see if a skin suction device will improve outcomes. After testing the vaccine on monkeys, Cellid entered into a partnership with the South Korean chemical manufacturer LG Chem to manufacture the vaccine.In December 2020, Cellid registered a Phase 1 trial for AdCLD-CoV19, and a Phase 2 trial launched in June 2021. After reviewing clinical trial results, the World Health Organization gave emergency authorization to the vaccine on June 1, 2021.On May 4, the European Medicines Agency said it was launching a rolling review of CoronaVac, which will accelerate Sinovacs marketing authorization if the company decides to apply for one. The vaccine contains fragments of coronavirus spike proteins and is delivered in three doses: two injections and one nasal spray. On April 29, 2021, they registered a Phase 1 trial in Turkey. In a paper published in September 2021, researchers reported that the efficacy of the vaccine at preventing Covid-19 illness was 93.2 percent. Sinopharms two other vaccine candidates, one developed with the Beijing Institute and one developed with the Wuhan Institute, use inactivated coronaviruses to develop immunity. researchers reported 15 cases of the unusual clots in nearly 8 million people who received the vaccine. Positive results from the trial, released on Dec. 22, suggested that the vaccine could produce a significant immune response without adverse reactions. They will be measuring the vaccines efficacy only against severe disease, rather than against any symptomatic cases of Covid.On May 10, 2022, Inovio said that it would discontinue its Phase 3 trial and focus attention on testing the vaccine as a booster. Updated June 13, 2022, PHASE 2 PHASE 3 COMBINED PHASES Data sources: The Covid-19 (coronavirus) vaccinations information displayed is collected and maintained by Our World in Data from official reports. The researchers registered a Phase 1 clinical trial in Japan a year later. Vaccinename: Vaxzevria (also known as AZD1222, or Covishield in India) Preclinical studies suggest that the vaccine is effective against emerging variants, the companies said in April 2022. The trial began on May 23, 2022. The vaccine had an efficacy of 77.8 percent against symptomatic Covid-19, and its efficacy against severe Covid-19 was 93.4 percent. in July 2021. The company has created vaccines for Covid-19 based on RNA molecules that can make copies of themselves, increasing the production of viral proteins from each cell. By September, COVAX had lowered its 2021 forecast of Johnson & Johnson vaccines to only 180 million doses. Other viral vectors slowly replicate, carrying coronavirus proteins on their surface. In January 2022, Dr. Petrovsky told the Australian news service News.com.au that the Phase 3 trials in Iran showed Spikogen was 60 to 65 percent effective against the Delta variant. But the results were disappointing, leading the company to reformulate a new version of the vaccine, called AdCLD-CoV19-1.Cellid finished administering the updated vaccine to Phase 1 volunteers in October 2021 and applied to run a Phase 2/3 trial the following month. Because it only needs to be refrigerated rather than frozen, it can be used far more widely than mRNA vaccines. The rollout of COVID-19 vaccine is expected to begin in the near. Updated March 18, 2022, PHASE 2 They began using Johnson & Johnsons instead. On June 29, VBI released preliminary results from the trial, showing that volunteers produced high levels of antibodies without any serious side effects. Cuban regulators gave emergency authorization for the use of Soberana Plus in Covid-19 survivors on Sept. 23. Draft landscape of COVID-19 vaccine candidates, The draft landscape of COVID-19 vaccine candidates contains information on vaccine candidates collected through public information (e.g. On Nov. 3, 2021, Covaxin became the first Indian vaccine to receive emergency use authorization from the World Health Organization.In June 2021, Bharat Biotech set out to bring Covaxin to the United States. The small San Francisco company Vaxart specializes in developing oral vaccines. EMERGENCY USE IN TURKEY Type: Muscle injection China expanded its authorization to include children and adolescents on June 4. Taiwan-based vaccine maker Medigen created a vaccine containing a combination of spike proteins and an adjuvant from Dynavax. Later, it promised to distribute AstraZeneca vaccines to other countries. A British study showed that Comirnaty had an effectiveness of 88 percent against infection with Delta, the variant first identified in India. In January 2021, the vaccine moved on to a Phase 2 trial. Both Novavaxs prototype vaccine and a Omicron-specific vaccine produced antibodies against new Omicron subvariants.Novavax announced on July 19 that it was working with SK bioscience to manufacture the Omicron-specific vaccine in pre-filled syringes as early as 2023.On Aug. 15, 2022, Novavax applied to the F.D.A. Phase 3 trials could begin in early 2022. Vaccine experts questioned the effort, since the company had yet to release detailed clinical data showing the safety and efficacy of Spikogen. APPROVED IN CANADA In an earnings report on Oct. 28, Sanofi said it expected results from its new Phase 3 trial by the end of 2021, but on Dec. 15, the company announced the trial would continue into early 2022 because too few participants have gotten sick with Covid-19.Finally, in February 2022, Sanofi had results to share. But the Korean Biomedical Review reported that AstraZeneca would not be supplying the vaccine, raising doubts about the trials prospects. Newsweek selected only deaths as an adverse event, and selected the COVID vaccine as the only vaccine in the dataset. In February 2022, Clover announced that in 2022 it plans to seek authorization from the World Health Organization, the European Medicines Agency, and other regulators to use their vaccine as a universal booster. In April 2021, the company announced that the trial had delivered positive results and launched a Phase 3 trial on 4,000 volunteers in the United Kingdom. Efficacy: 72% in United States, 68% in Brazil and 64% in South Africa Sinai launched a Phase 1 trial to study NDV-HXP-S as a booster for people vaccinated with other vaccines. A Phase 3 trial on 10,000 volunteers found that a Pfizer-BioNTech booster has an efficacy of 95.6 percent against disease, at a time when the Delta variant was dominant.As the Delta variant fueled a new surge of cases in Israel, the country began providing a third dose of Comirnaty as a booster. On Nov. 9, 2020, New York-based Pfizer and the German company BioNTech made history by announcing that their coronavirus vaccine had an efficacy rate of over 90 percent, far surpassing expectations. EMERGENCY USE IN TAIWAN Results from a Peru trial suggest that the vaccine was 50.4 percent effective in preventing infections among healthcare workers, Reuters reported on Aug. 13.After the vaccine was authorized in the United Arab Emirates, researchers there kept track of people who received the vaccine. Instead, the dose is loaded into a handheld device and shot directly into cell tissue through a jet spray of fluid. Of those deaths, 495 occurred following a Moderna shot, and 475 occurred following a Pfizer shot. Its effectiveness against hospitalization from Delta was 96 percent.On Dec. 8, Pfizer and BioNTech announced that the Omicron variant greatly reduced the ability of vaccine antibodies to neutralize the coronavirus. EMERGENCY USE IN INDIA, BOTSWANA The researchers registered a Phase 3 trial on Sept. 5, 2021, but the registry was later removed. A representative from Meissa described the ongoing Phase 1 trial at a July 2022 White House vaccine summit. While volunteers produced antibodies against the coronavirus, the trial was too small to determine the efficacy of CoviVac against Covid-19.In June 2022, the Chumakov Center created an entry for the Phase 3 trial of CoviVac on a registry maintained by the U.S. National Institutes of Health. Studies carried out in the spring of 2021 on monkeys and hamsters demonstrated that the vaccine provided the animals with protection against infection. In January 2022, the company announced promising initial results from the trial.In a financial report in August 2022, Gritstone bio announced that three additional Phase 1 trials were underway, including volunteers with immune systems compromised by HIV and B cell deficiencies. Updated April 3, 2022, ABANDONED They then infected insect cells with the virus, causing them to make the molecule in huge amounts. Updated July 23, 2022, PHASE 1 In the trial, which was registered on March 9, 2022, the researchers plan to measure antibody levels produced in volunteers who have already received two doses and a booster shot of widely used vaccines. Type: Muscle injection EMERGENCY USE IN MANY COUNTRIES Updated April 29, 2022, ABANDONED Dose: 2 doses, 4 weeks apart APPROVED IN U.S., ELSEWHERE TRIAL RESULTS After getting promising results from preliminary studies in monkeys and humans, Novavax launched a Phase 2 trial on 2,900 people in South Africa in August 2020, and the next month it launched a Phase 3 trial with up to 15,000 volunteers in the United Kingdom. But the Institute has decided against advancing Covivac to Phase 3.In March 2022, researchers at Mt. Get the facts about COVID-19 vaccines - Mayo Clinic It was also the first to be shown to be safe and effective with just one dose rather than two. Vietnam news agencies announced that Nanocovax entered a Phase 2 trial in February 2021. The university is also testing an mRNA vaccine. Updated June 13, 2022, PHASE 3 COMBINED PHASES: One way to accelerate vaccine development is to combine phases. But manufacturing woes drastically slowed its rollout. More studies on monkeys released in February 2022 showed that the vaccine produced antibodies against a range of variants.The companys stock price increased 3,600 percent in the first half of 2020. The researchers inactivated the NDVs with chemicals and combined them with immune-boosting chemicals called adjuvants. As of Jan. 31, the Wuhan coronavirus is officially a public health emergency in the United States, Alex Azar, secretary of the US Department of Health and Human Services (HHS), announced at a White House press briefing. On Sept. 29, Jiangsu announced that it would merge with Shenzhen Rhegen Biotechnology to become a new company called Wuhan Rhecogen Biotechnology. The company became embroiled in several lawsuits with stockholders and a company partner. The researchers began dosing participants for their Phase 2 trial on May 28. This was based on the research conducted by Aix-Marseille University Faculty Member Dr. Herve Seligmann and Engineer Haim Yativ. Emergency use in: Belarus, Cuba, Nicaragua. told the South China Morning Post that the vaccine only requires one week between doses. The vaccine is relatively easy to manufacture because the proteins can be produced by fermenting yeast. The day is reset after midnight GMT+0. Updated Feb. 7, 2022, PHASE 1 The Indonesian pharmaceutical company Kalbe Farma pledged in April to buy 10 million doses of Genexines vaccine if it was proven to be safe and effective. Efficacy: Unknown In September, Cuba agreed to sell 10 million doses of Abdala to Vietnam, which has granted the vaccine emergency authorization. Additionally, 108,806,974 people or 33% of the population have received a booster dose. On Dec. 10, 2020, Nanogen Biopharmaceutical in Vietnam began recruiting 60 volunteers for a Phase 1 trial of their protein-based vaccine Nanocovax. Researchers at the Hong Kong biotechnology company DreamTec Limited have made a Covid-19 vaccine by adding genes to harmless bacteria spores. SAGE advises WHO on overall global policies and strategies, ranging from vaccines and technology, research and development, to delivery of immunization and its linkages with other health interventions. Despite the disappointing results, the company moved ahead with preparing an application to the European Union for emergency authorization for the use of the vaccine in people 60 and under. Approved for use in: Bahrain, Brazil, Canada, New Zealand, Saudi Arabia, Switzerland, United States. The vaccine is based on a coronavirus protein which is produced in insect cells by genetically altered viruses. Even though the candidates ability to generate antibodies has been disappointing, it said, the trials would continue. By February 2022 they had raised over $1 million. Reuters reported in February 2022 that Walvax had a capacity to make 400 million doses and planned to increase their production. Tass reported on Jan. 18, 2022 that the Gamelaya Institute director said Sputnik V demonstrates around 75 percent efficacy against the Omicron variant, but the data supporting this conclusion have not yet been released. On June 30, 2021, Clover announced an agreement to provide 400 million doses to COVAX, the initiative to deliver vaccines to low- and middle-income countries. Their prototype vaccine, known as HGC019, safely provoked animals to make antibodies to the coronavirus. On Oct. 29, 2021, the company announced it had won approval from the South African government to start a Phase 1 trial. 100% against severe disease and hospitalization, with the European Union for 300 million doses, Investments from the Coalition for Epidemic Preparedness, produced high levels of antibodies without dangerous side effects, second-generation version of its plant-based vaccine, ones that have yet to spill over from animal hosts, inactivated coronaviruses to develop immunity, despite being fully vaccinated with Sinovac, 1.25 million doses, a tiny fraction of the order it had originally promised, can protect against the Alpha and Delta variants, Frequently Asked Questions About the Covid Data. Strategic Advisory Group of Experts (SAGE) on Immunization. In January 2021, Sanofi decided to help Pfizer and BioNTech make 100 million doses of their vaccine, and they reached a similar agreement with Johnson & Johnson in February.Meanwhile, Sanofi developed a stronger formulation of Vidprevtyn. Storage: Over a year at room temperature In a message to shareholders on Jan. 12, 2022, Oramed said it expected to launch Phase 2/3 trials in the second half of the year. On Aug. 31, 2022, the F.D.A. ACM-001 can be delivered as an intranasal spray. The vaccine designers hope to create a new version of the vaccine with proteins from other coronaviruses to offer protection that extends beyond Covid-19. Delays in funding and manufacturing slowed the studys launch until June 2021. Soberana 2 also contains aluminum hydroxide as an adjuvant to boost the immune system.After testing Soberana 2 in animals, Finlay researchers started a Phase 1 trial in October 2020, followed by a Phase 2 trial in December. In early 2020, they began work on a Covid-19 vaccine, called CVnCoV. WHO's COVID-19 dashboard also features the number of vaccine doses administered globally, with more detail provided on the dedicated COVID-19 vaccination dashboard. You can schedule your appointment online on cvs or walgreens websites. rejected its request for pre-qualification, casting doubt on its ultimate success. Type: Muscle injection The final results were posted online on July 2 and appeared in the Lancet on Nov. 11. In the announcement the company said it was planning a Phase 3 trial for later in 2022. For more details, see How the Sinopharm Vaccine Works. In March 2022, the Wall Street Journal reported that the company had resolved its manufacturing problems. As of February 2022, Bharat Biotech had distributed 200 million doses. A spokesperson for Tetherex said on Jan. 18, 2022, that the trial remains ongoing. But Finlay researchers are specifically tailoring this vaccine to people who have already had Covid-19 a first of its kind. Their booster trial is currently in Phase 2.The World Health Organization selected Inovios vaccine as one its first candidates in the Solidarity Trial Vaccine study. A screenshot of the data Newsweek received based on a WONDER search of the VAERS database. Caribbean After the SARS epidemic in 2002, Baylor College of Medicine researchers began developing a vaccine that could prevent a new outbreak. In February 2021, VBI registered a placebo-controlled Phase 1/2 trial in Canada on 780 volunteers, comparing the effects from using one or two doses. But as approved vaccines became easier to get in Canada, some volunteers began dropping out of the trial, Saskatoons CTV News reported. In May 2022, Arcturus reported that ARCT-154 performed well as a booster for people vaccinated with Comirnaty and later reported that it raised antibodies against the Omicron variant and its subvariants.On February 28, 2022, Arcturus announced it had applied for emergency use authorization in Vietnam for ARCT-154. Vaccinename: DoCo-Pro-RBD-1 After the single-dose version of the vaccine was rolled out in Argentina, a study found that its effectiveness there was between 78.6 and 83.7 percent.Phase 2 human trials for an intranasal version of Sputnik V have begun, Tass reported on Feb. 15, 2022.Russian researchers are also working on modifying the vaccine for use in teenagers. But in December, Eyegene said that it will receive help from the Korean government in recruiting patients for the trial, after experiencing difficulties finding enough eligible participants. In May it further expanded its booster authorization to children as young as five.On March 29, the F.D.A. But on April 25, Valneva said that the E.M.A. Approved for use in: Canada (for ages 1864). Entos C.E.O. CEPI pledged an additional $36.9 million toward the development of the vaccine on Nov. 18.Clover launched a Phase 1 trial in June 2020, and in December the company announced that the vaccine triggered a high level of antibodies. TRIAL RESULTSThe researchers launched clinical trials in June 2020. Injected into the body, these inactivated viruses cannot infect cells, but they can draw the attention of the immune system. Chinese researchers from AIM Vaccine and Liverna Therapeutics have developed an mRNA vaccine against the coronavirus. (Trial conducted when Delta and Omicron were dominant.) Type: Muscle injection Scancell broadened the trial to include individuals with prior infection or other vaccines in March. They have yet to provide a timeline for the development of an updated vaccine. Dose: 2 doses, 3 weeks apart Researchers began dosing trial participants in Iran on April 26. It contains an adenovirus called Ad5 (the same viral vector in CanSinoBios vaccine and in Russias Sputnik V).When Vaxart gave the pill to mice, they produced antibodies against the coronavirus. To make the vaccine, researchers started off with another virus, called respiratory syncytial virus (RSV for short). In November 2021, the F.D.A. Russia began distributing the vaccine, known as Sputnik V, in fall 2020, and it is now widely used around the world. Both kinds have been tested as vaccines over a number of years. said in February 2022 that it had cleared them for shipment.In South Africa, a small trial failed to demonstrate that it protected people against the Beta variant, which had become predominant in the country. In October 2021 they registered a Phase 3 trial to test their vaccine as a booster for an inactivated virus vaccine. VACCINE DEVELOPMENTIn early 2020, Sinovac developed the Coronavac vaccine based on inactivated coronaviruses. Canaries and Balearics information is provided by the Spanish Ministry of Health. On Feb. 22, 2021, the company launched a new Phase 2 trial, which showed that the new version produced strong immune responses. The following month, Emergent announced that it would resume production of the vaccines from its Baltimore plant after it receives authorization from the F.D.A. In their announcement, Cuban regulators said that the immune response in children was similar to adults who received Soberana 2. In the spring of 2020, the Israel Institute for Biological Research started work on a coronavirus vaccine based on vesicular stomatitis viruses. An advisory panel to the F.D.A. Dose: 2 doses, 2 weeks apart Updated April 3, 2022, ABANDONED authorized the Comirnaty booster for all adults 18 and older. In June 2021, after the F.D.A. Cubas Finlay Vaccine Institute developed a vaccine known as Soberana 2. On Sept. 17, they finished administering the vaccine to Phase 2 volunteers and made plans for a Phase 3 trial in which they would compare it against the AstraZeneca vaccine, Vaxzevria. Results from that trial suggested that Covaxin was more effective in children than in adults. SK Bioscience, a South Korean vaccine maker, won approval on Nov. 23, 2020 from the countrys Ministry of Food and Drug Safety for a vaccine called NBP2001. The vaccine, called CORVax12, consisted of a loop of DNA that encodes both the spike protein and IL-12. Early use in: Russia. In January 2022, a team of scientists from China and the U.A.E. In the Phase 1 clinical trial, researchers will evaluate CV2CoV as a booster shot. On Jan. 22, 2021, the researchers registered another Phase 2 trial with 4,000 volunteers. Scientists at the University of Georgia and the University of Iowa have developed a vaccine based on canine parainfluenza virus, which has never been found to cause disease in humans. The Omicron variant proved able to evade some of the immunity provided by the vaccine, making the vaccine less effective at protecting against infection. Pfizer has asked the F.D.A. The spike protein provokes the body to make antibodies, while the pieces of other proteins train the immune system to recognize infected cells and kill them.In addition, the researchers created an RNA molecule with the same genetic instructions, which they put in a shell.